SCIT group
The injection site was either lateral to the distal third of the upper arm or dorsal to the middle third of the forearm, and treatment consisted of two phases which were dose accumulation and dose maintenance.Allergen injection with a starting dose of 50 TU/mL was injected once a week for up to 15 weeks. In the first 12 weeks, patients were injected with (1) 0.1mL, 0.2mL, 0.4mL, and 0.8mL of allergen at 50 TU/mL (concentration grade 1); (2) 0.1mL, 0.2mL, 0.4mL, and 0.8mL of allergen at 500 TU/mL (concentration grade 2); (3) 0.1mL, 0.2mL, 0.4mL, and 0.6mL of allergen at 5000 TU/mL (concentration grade 3). In 13, 14 and 15 week, patients were injected with 0.8mL, 1.0mL and 1.0mL of allergen at 5000 TU/mL (concentration grade 3), respectively. Dose maintenance phase started after 15 weeks, during which the allergen injection 1.0mL dose of 5000 TU/mL (concentration grade 3) was kept unchanged, and the interval between each injection was 4 weeks with the total treatment course of 3 years. Evaluations of SCIT were in the same way as ICLIT.